Back to today’s briefing

Story perspectives

Pfizer Acquires Metsera for $10 Billion Amid Antitrust Concerns

11/9/2025

28 3 Full Breakdown

Summary

Story summary

Pfizer Inc. has finalized a $10 billion acquisition of Metsera Inc., paying $86.25 per share with a $65.60 upfront cash payment and potential milestone payments.
Metsera's board endorsed the offer, citing lower regulatory risks than Novo Nordisk's bid.
The U.S. Federal Trade Commission raised antitrust concerns about Novo Nordisk's bid.
Pfizer and Metsera expect the deal to close shortly after Metsera's shareholder meeting on November 13.

History

Historical Context

In 2000, Pfizer acquired Warner-Lambert for $90 billion, significantly enhancing its pharmaceutical portfolio and creating the second-largest drug company globally. This merger followed Warner-Lambert's history of strategic acquisitions since its formation in 1955, including the successful launch of Lipitor in 1997. The deal faced regulatory scrutiny, reflecting ongoing antitrust challenges in the pharmaceutical sector.

1 of 2

Story summary

Pfizer Inc. has finalized a $10 billion acquisition of Metsera Inc., paying $86.25 per share with a $65.60 upfront cash payment and potential milestone payments.
Metsera's board endorsed the offer, citing lower regulatory risks than Novo Nordisk's bid.
The U.S. Federal Trade Commission raised antitrust concerns about Novo Nordisk's bid.
Pfizer and Metsera expect the deal to close shortly after Metsera's shareholder meeting on November 13.

1 / 2